News & Updates
Filter by Specialty:
Long-term hydrochlorothiazide use ups risk of skin cancer
Using hydrochlorothiazide (HCTZ) for longer durations and in higher cumulative doses increases the risks for keratinocyte carcinoma and melanoma, reveals a study.
Long-term hydrochlorothiazide use ups risk of skin cancer
17 Aug 2023
Demedicalized delivery of PrEP possible, improves access
A peer-led demedicalized delivery of same-day HIV pre-exposure prophylaxis (PrEP) in various community centres is feasible, suggests a Philippines study presented at the recent IAS 2023.
Demedicalized delivery of PrEP possible, improves access
16 Aug 2023
Meeting gender-affirming needs tied to accessing HIV services among transgender people
Having met gender-affirming care needs among transgender people is associated with accessing HIV-related services in a community-led clinic, as shown in a Philippines study presented at IAS 2023.
Meeting gender-affirming needs tied to accessing HIV services among transgender people
16 Aug 2023
Dapagliflozin cuts risk of total HF events, CV deaths in HF patients
In a prespecified analysis of the DELIVER* study, the sodium glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the rate of total** heart failure (HF) events or cardiovascular (CV) deaths in HF patients with mildly reduced or preserved ejection fraction (HFmrEF or HFpEF).
Dapagliflozin cuts risk of total HF events, CV deaths in HF patients
16 Aug 2023
Chemo-free anti-ERBB2 therapy viable in ERBB2-positive MBC
In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.
